SGMT Stock Summary and Trading Ideas (Sagimet Biosciences - Series A | NASDAQ:SGMT)

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences - Series A trades on the NASDAQ stock market under the symbol SGMT.

As of May 18, 2026, SGMT stock price declined to $6.66 with 1,090,640 million shares trading.

SGMT has a beta of 1.54, meaning it tends to be more sensitive to market movements. SGMT has a correlation of 0.05 to the broad based SPY ETF.

SGMT has a market cap of $411.27 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that SGMT belongs to (by Net Assets): VTI, VXF, IBB, DFAS, IWC.

SGMT has outperformed the market in the last year with a return of +101.2%, while the SPY ETF gained +26.3%. In the last 3 month period, SGMT beat the market returning +31.6%, while SPY returned +8.6%. However, in the most recent 2 weeks SGMT has underperformed the stock market by returning -12.5%, while SPY returned +2.5%.

SGMT support price is $6.47 and resistance is $7.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMT shares will trade within this expected range on the day.